These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1362276)

  • 1. Tardive dyskinesia and diabetes mellitus.
    Ganzini L; Casey DE; Hoffman WF; Heintz RT
    Psychopharmacol Bull; 1992; 28(3):281-6. PubMed ID: 1362276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.
    Ganzini L; Casey DE; Hoffman WF; McCall AL
    Arch Intern Med; 1993 Jun; 153(12):1469-75. PubMed ID: 8512437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.
    Ghadirian AM; Annable L; Bélanger MC; Chouinard G
    J Clin Psychiatry; 1996 Jan; 57(1):22-8. PubMed ID: 8543543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study.
    Raja M; Azzoni A
    Hum Psychopharmacol; 2002 Jan; 17(1):61-3. PubMed ID: 12404708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia in India: a prevalence study.
    Doongaji DR; Jeste DV; Jape NM; Sheth AS; Apte JS; Vahia VN; Desai AB; Vahora SA; Thatte S; Vevaina T; Bharadwaj J
    J Clin Psychopharmacol; 1982 Oct; 2(5):341-4. PubMed ID: 6127352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients.
    Hansen TE; Brown WL; Weigel RM; Casey DE
    J Clin Psychiatry; 1988 Apr; 49(4):139-41. PubMed ID: 2895762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
    Ulrich S; Sandmann U; Genz A
    Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of tardive dyskinesia.
    Gardos G; Cole JO; Haskell D; Marby D; Paine SS; Moore P
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):31S-37S. PubMed ID: 2906068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.
    Harris MJ; Panton D; Caligiuri MP; Krull AJ; Tran-Johnson TK; Jeste DV
    Psychopharmacol Bull; 1992; 28(1):87-92. PubMed ID: 1609047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution.
    Akbostanci MC; Atbaşoğlu EC; Balaban H
    Acta Neurol Belg; 1999 Sep; 99(3):176-81. PubMed ID: 10544725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epidemiology of tardive dyskinesias in the Maghreb].
    Moussaoui D; Douki S; Bentounsi B; Otarid A; Chorfi M; Mamou A; Benamor L
    Encephale; 1988 Sep; 14 Spec No():203-8. PubMed ID: 2905647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tardive dyskinesia in outpatients on depot phenothiazine.
    Neehall J
    West Indian Med J; 1989 Dec; 38(4):228-33. PubMed ID: 2576166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.
    Ganzini L; Heintz RT; Hoffman WF; Casey DE
    Arch Gen Psychiatry; 1991 Mar; 48(3):259-63. PubMed ID: 1671743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A summary of current knowledge of tardive dyskinesia.
    Baldessarini RJ
    Encephale; 1988 Sep; 14 Spec No():263-8. PubMed ID: 2905654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
    Glazer WM; Morgenstern H; Doucette JT
    J Clin Psychiatry; 1993 Apr; 54(4):133-9. PubMed ID: 8098030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Affective disorders and tardive dyskinesia.
    Casey DE
    Encephale; 1988 Sep; 14 Spec No():221-6. PubMed ID: 2905650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.